JP2024504372A5 - - Google Patents
Info
- Publication number
- JP2024504372A5 JP2024504372A5 JP2023544305A JP2023544305A JP2024504372A5 JP 2024504372 A5 JP2024504372 A5 JP 2024504372A5 JP 2023544305 A JP2023544305 A JP 2023544305A JP 2023544305 A JP2023544305 A JP 2023544305A JP 2024504372 A5 JP2024504372 A5 JP 2024504372A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- approximately
- less
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163140749P | 2021-01-22 | 2021-01-22 | |
| US63/140,749 | 2021-01-22 | ||
| PCT/US2022/013417 WO2022159771A1 (en) | 2021-01-22 | 2022-01-21 | Anti-pd-l1 monoclonal antibodies and fusion proteins with interleukin-15 (il-15), interleukin-15 receptor 15 alpha or interleukin-2 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024504372A JP2024504372A (ja) | 2024-01-31 |
| JP2024504372A5 true JP2024504372A5 (https=) | 2025-01-23 |
Family
ID=80447580
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023544305A Pending JP2024504372A (ja) | 2021-01-22 | 2022-01-21 | 抗ｐｄ－ｌ１モノクローナル抗体及びインターロイキン１５（ｉｌ－１５）、インターロイキン１５受容体１５アルファまたはインターロイキン２との融合タンパク質 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20250340646A1 (https=) |
| EP (1) | EP4281186A1 (https=) |
| JP (1) | JP2024504372A (https=) |
| KR (1) | KR20230148169A (https=) |
| CN (1) | CN117083297A (https=) |
| AU (1) | AU2022211410A1 (https=) |
| CA (1) | CA3205670A1 (https=) |
| IL (1) | IL304588A (https=) |
| WO (1) | WO2022159771A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11633488B2 (en) | 2020-01-10 | 2023-04-25 | Bright Peak Therapeutics Ag | Modified IL-2 polypeptides and uses thereof |
| AU2022306974A1 (en) | 2021-07-09 | 2024-01-04 | Bright Peak Therapeutics Ag | Modified il-2 polypeptides for treatment of inflammatory and autoimmune diseases |
| WO2023281480A1 (en) * | 2021-07-09 | 2023-01-12 | Bright Peak Therapeutics Ag | Conjugates of checkpoint inhibitors with il-2, and uses thereof |
| WO2024263698A1 (en) * | 2023-06-22 | 2024-12-26 | Memorial Sloan-Kettering Cancer Center | Anti-pd-l1 immunoglobulin-related compositions comprising il-15-il-15ra fusion polypeptides and uses thereof |
| WO2025119308A1 (zh) * | 2023-12-08 | 2025-06-12 | 百奥泰生物制药股份有限公司 | 融合蛋白及其应用 |
| WO2025195291A1 (zh) * | 2024-03-16 | 2025-09-25 | 百奥泰生物制药股份有限公司 | 治疗肿瘤的方法和用途 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4604377A (en) | 1984-03-28 | 1986-08-05 | Cetus Corporation | Pharmaceutical compositions of microbially produced interleukin-2 |
| US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
| US7018809B1 (en) | 1991-09-19 | 2006-03-28 | Genentech, Inc. | Expression of functional antibody fragments |
| US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
| US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
| ATE332368T1 (de) | 1997-01-21 | 2006-07-15 | Gen Hospital Corp | Selektion von proteinen mittels rns-protein fusionen |
| PL209392B1 (pl) | 1999-01-15 | 2011-08-31 | Genentech Inc | Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała |
| US7083784B2 (en) | 2000-12-12 | 2006-08-01 | Medimmune, Inc. | Molecules with extended half-lives, compositions and uses thereof |
| US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| US8388955B2 (en) | 2003-03-03 | 2013-03-05 | Xencor, Inc. | Fc variants |
| AU2005304624B2 (en) | 2004-11-12 | 2010-10-07 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| US8119772B2 (en) | 2006-09-29 | 2012-02-21 | California Institute Of Technology | MART-1 T cell receptors |
| DK3186283T3 (da) * | 2014-08-29 | 2020-03-02 | Hoffmann La Roche | Kombinationsbehandling med tumormålrettede IL-2- immuncytokinervarianter og antistoffer mod humant PD-L1 |
| JP6839074B2 (ja) * | 2014-09-17 | 2021-03-03 | ノバルティス アーゲー | 養子免疫療法のためのキメラ受容体での細胞毒性細胞のターゲティング |
| AU2019359475A1 (en) * | 2018-10-12 | 2021-05-20 | Xencor, Inc. | PD-1 targeted IL-15/IL-15Ralpha Fc fusion proteins and uses in combination therapies thereof |
| WO2020081493A1 (en) * | 2018-10-16 | 2020-04-23 | Molecular Templates, Inc. | Pd-l1 binding proteins |
| WO2020165374A1 (en) * | 2019-02-14 | 2020-08-20 | Ose Immunotherapeutics | Bifunctional molecule comprising il-15ra |
-
2022
- 2022-01-21 JP JP2023544305A patent/JP2024504372A/ja active Pending
- 2022-01-21 WO PCT/US2022/013417 patent/WO2022159771A1/en not_active Ceased
- 2022-01-21 KR KR1020237028520A patent/KR20230148169A/ko active Pending
- 2022-01-21 AU AU2022211410A patent/AU2022211410A1/en active Pending
- 2022-01-21 EP EP22703782.7A patent/EP4281186A1/en active Pending
- 2022-01-21 CN CN202280022519.2A patent/CN117083297A/zh active Pending
- 2022-01-21 CA CA3205670A patent/CA3205670A1/en active Pending
- 2022-01-21 US US18/262,122 patent/US20250340646A1/en active Pending
-
2023
- 2023-07-19 IL IL304588A patent/IL304588A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024504372A5 (https=) | ||
| RU2573893C2 (ru) | Фармацевтические композиции с устойчивостью к растворимому сеа | |
| JP2022535130A5 (https=) | ||
| JP2022521937A5 (https=) | ||
| JP2022536898A5 (https=) | ||
| CN111527109A (zh) | 以抗体Fc区为骨架的融合蛋白二聚体及其应用 | |
| HRP20250443T1 (hr) | Proteini koji vežu dll3/cd3 za liječenje raka | |
| RU2019134352A (ru) | Новые биспецифические антигенсвязывающие молекулы, обладающие способностью специфически связываться с cd40 и fap | |
| US20240059791A1 (en) | Trifunctional fusion protein containing tumor-associated antigen (taa) antibody and application thereof | |
| JP2022551081A5 (https=) | ||
| TW201444872A (zh) | 抗Ｃ－ＭＥＴ串聯Ｆｃ雙特異性抗體 | |
| RU2019129569A (ru) | ИММУНОЦИТОКИН, ВКЛЮЧАЮЩИЙ ГЕТЕРОДИМЕРНЫЙ БЕЛКОВЫЙ КОМПЛЕКС НА ОСНОВЕ IL-15/IL-15Rα, И ЕГО ПРИМЕНЕНИЕ | |
| JP2022549276A5 (https=) | ||
| JP2023550419A5 (https=) | ||
| WO2022125694A1 (en) | Fusions of interleukin polypeptides with bispecific antigen binding molecules for modulating immune cell function | |
| JP2023545099A5 (https=) | ||
| JP2023544143A5 (https=) | ||
| CN113490690A (zh) | 异源二聚体融合蛋白 | |
| JP2024510811A5 (https=) | ||
| Chen et al. | Immunoglobulin gamma‐like therapeutic bispecific antibody formats for tumor therapy | |
| JP2023543896A5 (https=) | ||
| JP2025504795A5 (https=) | ||
| JP2024521701A (ja) | 抗ｃｄ１３７抗体及びその使用方法 | |
| JP7738914B2 (ja) | ＴｒｉＡｘ抗体の組成、その製造方法及び使用方法 | |
| JPWO2022102768A5 (https=) |